BCR and chronic myelogenous leukemia, BCR-ABL1 positive: A recently published study showed that the HFA-ICOS risk score performs well in patients with CML treated with BCR::ABL1 TKIs, however the main limitations were that ischaemic events were the only reported CV events and the low number of patients included, resulting in a call for larger studies [19].